Patricia Millican - Metacrine Chief Officer
| MTCRDelisted Stock | USD 0.49 0.00 0.00% |
Insider
Patricia Millican is Chief Officer of Metacrine
| Age | 50 |
| Phone | 858 369 7800 |
| Web | https://www.metacrine.com |
Metacrine Management Efficiency
The company has return on total asset (ROA) of (0.3686) % which means that it has lost $0.3686 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9072) %, meaning that it created substantial loss on money invested by shareholders. Metacrine's management efficiency ratios could be used to measure how well Metacrine manages its routine affairs as well as how well it operates its assets and liabilities.Metacrine currently holds 13.3 M in liabilities with Debt to Equity (D/E) ratio of 0.33, which is about average as compared to similar companies. Metacrine has a current ratio of 21.84, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Metacrine's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Charles Williams | Surrozen | 44 | |
| David Hanley | Nuvation Bio | 54 | |
| Hoyoung MD | CytomX Therapeutics | 55 | |
| AO FRACP | Assembly Biosciences | 65 | |
| MBA MD | Monopar Therapeutics | 38 | |
| Scott Anderson | Anebulo Pharmaceuticals | N/A | |
| Jamie Moore | CytomX Therapeutics | N/A | |
| MBA BS | CytomX Therapeutics | 45 | |
| Mark Dudley | Instil Bio | N/A | |
| Christopher Ogden | CytomX Therapeutics | 40 | |
| Michael Newman | Indaptus Therapeutics | 68 | |
| Oleg Nodelman | Nuvation Bio | 44 | |
| W Vernon | Nuvation Bio | 65 | |
| Kristine Rosse | Protara Therapeutics | N/A | |
| MHROD SHRMSCP | Assembly Biosciences | N/A | |
| Michelle Doig | Nuvation Bio | 46 | |
| Timothy Moore | Instil Bio | 63 | |
| MS JD | Surrozen | 62 | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| MBA CFA | Vaccinex | 50 | |
| Kathryn Falberg | Nuvation Bio | 60 | |
Management Performance
| Return On Equity | -0.91 | |||
| Return On Asset | -0.37 |
Metacrine Leadership Team
Elected by the shareholders, the Metacrine's board of directors comprises two types of representatives: Metacrine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Metacrine. The board's role is to monitor Metacrine's management team and ensure that shareholders' interests are well served. Metacrine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Metacrine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patricia Millican, Chief Officer | ||
| Theresa Lowry, VP HR | ||
| Michael York, Chief Officer | ||
| MHS MD, CEO Pres |
Metacrine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Metacrine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.91 | |||
| Return On Asset | -0.37 | |||
| Current Valuation | (23.98 M) | |||
| Shares Outstanding | 42.57 M | |||
| Shares Owned By Insiders | 12.29 % | |||
| Shares Owned By Institutions | 35.96 % | |||
| Number Of Shares Shorted | 87.42 K | |||
| Price To Book | 0.40 X | |||
| Gross Profit | (45.47 M) | |||
| EBITDA | (60.71 M) |
Pair Trading with Metacrine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Metacrine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Metacrine will appreciate offsetting losses from the drop in the long position's value.Moving against Metacrine Stock
| 0.56 | CSLLY | CSL | PairCorr |
| 0.54 | CMXHF | CSL Limited | PairCorr |
| 0.51 | REGN | Regeneron Pharmaceuticals | PairCorr |
| 0.39 | NVO | Novo Nordisk AS | PairCorr |
| 0.39 | NONOF | Novo Nordisk AS | PairCorr |
The ability to find closely correlated positions to Metacrine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Metacrine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Metacrine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Metacrine to buy it.
The correlation of Metacrine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Metacrine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Metacrine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Metacrine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in Metacrine Stock
If you are still planning to invest in Metacrine check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Metacrine's history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |